CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure

Original Research2018;7:e009806

JOURNAL:JAHA Article Link

Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Ki Hong Choi Jin‐Oh Choi et al. Keywords: heart failure with midrange ejection fraction; HFmrEF; acute HF; β‐blocker; renin‐angiotensin system blocker; all‐cause mortality

FULL TEXT PDF